Latest News by Industry
• Pfizer said the booster dose did not show any safety concerns in the trial
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) on Tuesday asked the Food and Drug Administration to authorize a booster dose of its Covid-19 vaccine for children aged 5 to 11.
According to data released earlier this month from studies conducted by Pfizer on children in the specified age group, the booster shot showed a 36-fold increase in antibody levels against the omicron variant.
In January, the FDA had authorized Pfizer’s booster dose for teenagers aged 12 to 15 years amid the rapid spread of Omicron variant.
Pfizer said that the booster dose did not show any safety concerns in the trial.
According to the data provided by CDC, only 28% of the children in the age group of 5 to 11 years have received two doses of Covid-19 vaccine.
The protection provided by the Covid-19 vaccine against variants is observed to decline over time. Booster shots, therefore, have been manufactured by several vaccine makers to provide added protection against the virus.
Picture Credits: Reuters
ALSO READ: